A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45.

Authors :: Descamps, G.
Gomez-Bougie, P.
Venot, C.
Moreau, P.
Bataille, R.
Amiot, M.
Source :: British Journal of Cancer. 1/27/2009, Vol. 100 Issue 2, p366-369. 4p. 1 Black and White Photograph, 1 Graph.
Publication Year :: 2009
Abstract: The humanised form of an antagonistic anti-IGF-1R mAb (AVE1642) selectively inhibits the growth of CD45(neg) myeloma cells. AVE1642 strongly increased bortezomib-induced apoptosis, correlated with an increase of Noxa expression. These results support the therapeutic use of anti-IGF-1R/bortezomib in CD45(neg) Myeloma patients, particularly those with the most aggressive form, t(4,14). [ABSTRACT FROM AUTHOR]

Full Text Access

Tools